ABSSSI Market Forecast 2034: FDA, EMA and PDMA Approvals, Epidemiology, Therapies, Companies by DelveInsight | Kimyrsa, Sivextro, Nuzyra, Baxdela, Dalbavancin, Orbactiv, Levonadifloxacin/Linezolid,etc

June 10 06:51 2024
ABSSSI Market Forecast 2034: FDA, EMA and PDMA Approvals, Epidemiology, Therapies, Companies by DelveInsight | Kimyrsa, Sivextro, Nuzyra, Baxdela, Dalbavancin, Orbactiv, Levonadifloxacin/Linezolid,etc
ABSSSI Market
ABSSSI companies are Merck, Pfizer, Paratek Pharmaceutical, Melinta Therapeutics, Allergan, Novexel, Teva Pharma, Wockhardt, Durata Therapeutics, Cubist Pharmaceutical, Sonescence, Forest Laboratories, The Medicine Company and more.

(Albany, USA) DelveInsight’s “ABSSSI Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of ABSSSI, historical and forecasted epidemiology as well as the ABSSSI market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The ABSSSI market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted ABSSSI market size from 2020 to 2034, segmented by seven major markets. The Report also covers current ABSSSI treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the ABSSSI market.

 

Request for a Free Sample Report @ Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market Forecast

 

Some facts of the ABSSSI Market Report are:

  • According to DelveInsight, ABSSSI market size is expected to grow at a decent CAGR by 2034.
  • Leading ABSSSI companies working in the market are Merck, Pfizer, Paratek Pharmaceutical, Melinta Therapeutics, Allergan, Novexel, Teva Pharma, Wockhardt, Durata Therapeutics, Cubist Pharmaceutical, Sonescence, Forest Laboratories, The Medicine Company and Others.
  • Key ABSSSI Therapies expected to launch in the market are Kimyrsa, Sivextro, Nuzyra, Baxdela, Dalbavancin, Orbactiv, Levonadifloxacin/Linezolid, NXL103, and others.
  • As per Delveinsight’s analysis, the total 7MM Incident cases of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) were 7,259,777, out of which the highest Incident cases of this disease were seen in the United States.
  • As per DelveInsight’s estimate, there were 1,942,229 male patients and 1,406,442 female cases suffering from ABSSSI in the United States.
  • In United States, it is estimated that more than 15 million bacterial skin and skin structure infections occur, causing considerable morbidity.
  • Owing to the launch of upcoming therapies, the ABSSSI market size shall increase significantly during forecast period: 2020-2034.
  • In February 2020, Paratek Pharmaceuticals, Inc., launched NUZYRA intravenous and oral antibiotic in the treatment of ABSSSI.
  • In January 2018, Melinta Therapeutics, Inc., launched BAXDELA for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI).

 

ABSSSI Overview

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are a category of bacterial infections that involve the skin and underlying soft tissues. They typically present with signs and symptoms of infection such as redness, swelling, warmth, pain, and often drainage of pus. Common types of ABSSSI include cellulitis, erysipelas, wound infections, and major cutaneous abscesses.

ABSSSI are frequently caused by gram-positive bacteria, with Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA), being the most common pathogen. Other bacteria such as Streptococcus pyogenes can also be involved. Risk factors for ABSSSI include compromised skin integrity due to cuts, abrasions, surgical wounds, chronic skin conditions, and underlying diseases such as diabetes or immune deficiencies.

Diagnosis of ABSSSI is based on clinical examination and patient history. In some cases, cultures of wound exudate or blood tests may be performed to identify the causative organism and guide antibiotic therapy.

Treatment involves appropriate antibiotic therapy tailored to the suspected or confirmed pathogen, along with supportive care measures such as wound care and pain management. For MRSA infections, specific antibiotics like vancomycin, linezolid, or daptomycin may be required. Severe cases may necessitate hospitalization and intravenous antibiotics.

Prompt and effective treatment of ABSSSI is essential to prevent complications such as sepsis, chronic wounds, or the spread of infection. With proper medical management, most patients with ABSSSI recover fully.

 

Learn more about ABSSSI treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market

 

ABSSSI Market 

The ABSSSI market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted ABSSSI market trends by analyzing the impact of current ABSSSI therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the ABSSSI market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated ABSSSI market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the ABSSSI market in 7MM is expected to witness a major change in the study period 2020-2034.

 

ABSSSI Epidemiology 

The ABSSSI epidemiology section provides insights into the historical and current ABSSSI patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the ABSSSI market report also provides the diagnosed patient pool, trends, and assumptions. 

 

Explore more about ABSSSI Epidemiology @ Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Prevalence

 

ABSSSI Drugs Uptake

This section focuses on the uptake rate of the potential ABSSSI drugs recently launched in the ABSSSI market or expected to be launched in 2020-2034. The analysis covers the ABSSSI market uptake by drugs, patient uptake by therapies, and sales of each drug.   

ABSSSI Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on ABSSSI market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

ABSSSI Pipeline Development Activities

The ABSSSI report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses ABSSSI key players involved in developing targeted therapeutics.

 

Request for a sample report to understand more about the ABSSSI pipeline development activities @ Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Therapies and Drugs

 

ABSSSI Therapeutics Assessment

Major key companies are working proactively in the ABSSSI Therapeutics market to develop novel therapies which will drive the ABSSSI treatment markets in the upcoming years are Merck, Pfizer, Paratek Pharmaceutical, Melinta Therapeutics, Allergan, Novexel, Teva Pharma, Wockhardt, Durata Therapeutics, Cubist Pharmaceutical, Sonescence, Forest Laboratories, The Medicine Company and Others.

 

Learn more about the emerging ABSSSI therapies & key companies @ Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Clinical Trials and FDA Approvals

 

ABSSSI Report Key Insights

1. ABSSSI Patient Population

2. ABSSSI Market Size and Trends

3. Key Cross Competition in the ABSSSI Market

4. ABSSSI Market Dynamics (Key Drivers and Barriers)

5. ABSSSI Market Opportunities

6. ABSSSI Therapeutic Approaches

7. ABSSSI Pipeline Analysis

8. ABSSSI Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the ABSSSI Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. ABSSSI Competitive Intelligence Analysis

4. ABSSSI Market Overview at a Glance

5. ABSSSI Disease Background and Overview

6. ABSSSI Patient Journey

7. ABSSSI Epidemiology and Patient Population

8. ABSSSI Treatment Algorithm, Current Treatment, and Medical Practices

9. ABSSSI Unmet Needs

10. Key Endpoints of ABSSSI Treatment

11. ABSSSI Marketed Products

12. ABSSSI Emerging Therapies

13. ABSSSI Seven Major Market Analysis

14. Attribute Analysis

15. ABSSSI Market Outlook (7 major markets)

16. ABSSSI Access and Reimbursement Overview

17. KOL Views on the ABSSSI Market

18. ABSSSI Market Drivers

19. ABSSSI Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services